- Home
- SLGB vs CRIS Comparison
SLGB vs CRIS Comparison
Compare SLGB & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | CRIS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 20.6M |
| IPO Year | 2023 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SLGB | CRIS |
|---|---|---|
| Price | $0.32 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 318.0K | 139.0K |
| Earning Date | 05-16-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.34 | $0.18 |
| 52 Week High | $6.02 | $6.74 |
Technical Indicators
Market Signals| Indicator | SLGB | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 23.56 |
| Support Level | N/A | $0.80 |
| Resistance Level | $0.56 | $1.21 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.50 | 6.00 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC. The company focuses on industrial raw materials line-haul transportation business. The group focuses on developing a road-transport smart logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.